Infantile hepatic hemangioma: current state of the art, controversies, and perspectives

Zavras, Nick; Dimopoulou, Anastasia; Machairas, Nikolaos; Πασπάλα, Άννα; Vaos, George

doi:10.1007/s00431-019-03504-7

Cited by 44 publications

(68 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there are lack of effective specific antivirals or drug combinations available for the treatment of COVID-19 supported by high-quality evidence [24] , [25] , [26] , [27] , [28] , according to the current research findings, there are some potential drugs can help COVID-19 patients [29] , [30] , [31] , [32] , [33] , which requires a great deal of continuity research with high quality. At the same time, prognosis was one of the most concerned subject by researchers, especially for pregnant and children, which still has a lot of uncertainty for researchers to pay attention [34] .…”

Section: Discussionmentioning

confidence: 99%

Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping

Cao

Zhang

et al. 2021

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

Objectives To assess the reporting and methodological quality of COVID-19 systematic reviews, and to analyze trends and gaps in the quality, clinical topics, author countries, and populations of the reviews using an evidence mapping approach. Study Design and Setting A structured search for systematic reviews concerning COVID-19 was performed using PubMed, Embase, Cochrane Library, Campbell Library, Web of Science, CBM, WanFang Data, CNKI, and CQVIP from inception until June 2020. The quality of each review was assessed using the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2) checklist and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Results In total, 243 systematic reviews met the inclusion criteria, over 50% of which (128, 52.7%) were from 14 developing countries, with China contributing the most reviews (76, 31.3%). In terms of methodological quality of the studies, 30 (12.3%) were of moderate quality, 63 (25.9%) were of low quality, and 150 (61.7%) were of critically low quality. In terms of reporting quality, the median (interquartile range) PRISMA score was 14 (10–18). Regarding the topics of the reviews, 24 (9.9%) focused on the prevalence of COVID-19, 69 (28.4%) focused on the clinical manifestations, 30 (12.3%) focused on etiology, 43 (17.7%) focused on diagnosis, 65 (26.7%) focused on treatment, 104 (42.8%) focused on prognosis, and 25 (10.3%) focused on prevention. These studies mainly focused on general patients with COVID-19 (161, 66.3%), followed by children (22, 9.1%) and pregnant patients (18, 7.4%). Conclusion This study systematically evaluated the methodological and reporting quality of systematic reviews of COVID-19, summarizing and analyzing trends in their clinical topics, author countries, and study populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping

Cao

Zhang

et al. 2021

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

show abstract

“…In this study, suspected Kasabach-Merritt syndrome was found in 19 cases. In these patients, the platelet counts were less than 50×10 9 , the hemangioma diameters were greater than 8 cm, and there were no abnormalities in the prothrombin time and hemoglobin. Among these cases, 8 had platelet counts of less than 10×10 9 , 2 had platelet counts between 10×10 9 and 20×10 9 , 2 had platelet counts between 20×10 9 and 30×10 9 , and 7 had platelet counts between 30×10 9 and 50×10 9 .…”

Section: Therapeutic Motivation and Indicationsmentioning

confidence: 79%

“…A real-world multicenter study can reveal much more information about a disease than randomized clinical trials owing to the large sample size and full data sets that can be obtained. With the increased understanding of hepatic hemangioma, and especially with the rapid development of imaging technology (5-8), the detection rate and diagnostic accuracy of this disease have improved (1,9). In the present study, the ratio of male to female in-hospital patients with hepatic hemangioma was 1:1.9, which is similar to previous were treated once, 6.45% were treated twice, 1.99% were treated 3 times, and 2.37% were treated more than 3 times.…”

Section: Discussionmentioning

confidence: 99%

Real-world data on the clinicopathological traits and outcomes of hospitalized liver hemangioma patients: a multicenter study

Tang¹,

Wang²,

Mao³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: There is currently a lack of consensus regarding the clinical features, diagnosis, treatment indications and options, and risk assessment of hepatic hemangioma patients.Methods: This was a multicenter, real-world study that analyzed a large number of hepatic hemangioma cases in China and included patient data on epidemiology, diagnosis, treatment methods, and outcomes.Results: A total of 5,143 patients hospitalized for hepatic hemangioma were included, of whom 34.42% were male and 65.58% were female. The age distribution was concentrated between 30 and 60 years old, accounting for 87.41% of the patients. Among the hepatic hemangioma patients, 60.8% had only one tumor, with the most common pathological type being cavernous hemangioma (96.07% of cases). The treatment motivations and indications included anxiety, obvious clinical symptoms, rapid tumor growth, unclear diagnoses and acute emergencies. Overall, 41.4% of the patients were treated for psychological reasons, while 30.59% were treated because they presented obvious (primarily nonspecific) clinical symptoms.Hepatic resection was the main therapeutic method and was based on various indications. There were a small number of patients with Kasabach-Merritt syndrome, according to its generally recognized definition.Conclusions: Most patients in this study who were hospitalized for hepatic hemangioma did not meet the indications for requiring treatment. Surveillance is the recommended course of action for definitively diagnosed hepatic hemangioma, and a new classification system is needed to standardize the diagnosis of this condition.

show abstract

“…Diagnosis of HH mainly depends on imaging examination, without the need for puncture biopsy. The nal inclusion criteria were: (1) age ≥18 years and ≤80 years; (2) female patients pathologically diagnosed with invasive breast cancer and HH by abdominal ultrasound + contrast enhanced ultrasound + upper abdominal CT [4][9] ; (3) single or multiple HH found by imaging evaluation; (4) good liver function, Child-Pugh grade A; (5) generally good patient condition and cardio-pulmonary function that can tolerate operation. Exclusion criteria were: (1) incomplete follow-up data; (2) a history of upper abdominal operation; (3) previous effective treatment for HH; (4) combined with hepatic malignant tumors.…”

Section: Data Collectionmentioning

confidence: 99%

“…Hepatic hemangiomas(HH) are common benign vascular endothelial tumors of the liver [1] , with a higher incidence in women compared with men . They are more common in infants, and less frequent in adults [2] . HH do not cause apparent symptoms commonly,and are incidentally detected during clinical examination for other diseases [3] .…”

Section: Introductionmentioning

confidence: 99%

Clinical Observation and Retrospective Analysis of the Effect of Comprehensive Treatment on Hepatic Hemangiomas in HR Positive Breast Cancer Patients

Tan¹,

Hu²,

Sun³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: To retrospectively assess the size change of hepatic hemangiomas（HH） in hormone receptor positive (HR+) breast cancer patients after comprehensive treatment. Methods: Totally 364 confirmed invasive breast cancer cases with HH were diagnosed at the Breast Cancer Center of Yunnan Cancer Hospital in 2013-2018 by abdominal color Doppler ultrasound (ADUS) + contrast enhanced ultrasound (CEUS) and at least one upper abdominal CT imaging examination. Follow-up was 6-78 months, and changes in location, number and size of HH at different treatment stages were compared between the HR+ and 85 HR- groups. Subgroup analysis of patients receiving chemotherapy and endocrine therapy was also performed. Results: Totally 323 patients were enrolled, including 238 HR+ (73.7%) and 85 HR- (26.3%) cases. Changes in the longest diameter were similar in both groups (P=0.556), and size change of HH was not associated with axillary lymph node metastasis of breast cancer (P>0.05). HH showed no change during chemotherapy but was significantly enlarged after chemotherapy (P<0.01). There was no significant difference between the tamoxifen (TAM; endocrine drug) only and combination or sequential endocrine treatment (P>0.05) groups. Only the aromatase inhibitor group showed statistical significance (P<0.05) in the AI (letrozole, anastrozole and exemestane) group at the t1 time point. Conclusion: During chemotherapy and endocrine therapy for breast cancer patients with HH, the size of HH changes in some patients, while others develop new HH. No significant effect on size change of HH was observed in this study.

show abstract

Infantile hepatic hemangioma: current state of the art, controversies, and perspectives

Cited by 44 publications

References 64 publications

Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping

Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping

Real-world data on the clinicopathological traits and outcomes of hospitalized liver hemangioma patients: a multicenter study

Clinical Observation and Retrospective Analysis of the Effect of Comprehensive Treatment on Hepatic Hemangiomas in HR Positive Breast Cancer Patients

Contact Info

Product

Resources

About